IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the IMpower 130 trial, carboplatin/nab-paclitaxel + atezolizumab vs chemotherapy alone did not confirm OS improvement (median OS 14.4 vs 10.0 months, HR 0.98).
“although these results were not confirmed in the IMpower 130 trial comparing carboplatin/nab-paclitaxel + atezolizumab vs. chemotherapy alone (median OS 14.4 vs. 10.0 months, HR 0.98) [109].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Patel, V. G., Oh, W. K., & Galsky, M. D. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21631 · Cited by 1,017 · see citing works
Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 292 · see citing works
Lin, A., Wei, T., Meng, H., Luo, P., & Zhang, J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1062-7 · Cited by 263 · see citing works
Rodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 237 · see citing works
Chen, S., Zhang, Z., Zheng, X., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Cui, P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.562315 · Cited by 144 · see citing works
Borghaei, H., Langer, C. J., Paz‐Ares, L., Rodríguez‐Abreu, D., Halmos, B., Garassino, M. C., Houghton, B., Kurata, T., Cheng, Y., Lin, J., et al. (2020) · Cancer · doi:10.1002/cncr.33142 · Cited by 115 · see citing works
Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110 · see citing works
Peters, S., Reck, M., Smit, E. F., Mok, T. S. K., & Hellmann, M. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz109 · Cited by 107 · see citing works
Addeo, A., Banna, G. L., Metro, G., & Maïo, M. D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00264 · Cited by 102 · see citing works
Friedlaender, A., Banna, G. L., Malapelle, U., Pisapia, P., & Addeo, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00166 · Cited by 92 · see citing works
Immunotherapy for the First-Line Treatment of Patients with Metastatic Non–Small Cell Lung Cancer
Martínez, P., Peters, S., Stammers, T. A., & Soria, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3904 · Cited by 82 · see citing works
“For TKI-pretreated patients with EGFR- or ALK-sensitizing alterations, data from the IMpower150 study suggested a median PFS and OS advantage for the ACPB regimen for (20), but this advantage was not seen in the IMpower130 study using ACnP without bevacizumab, suggesting an immunomodulatory role for bevacizumab.”
BackgroundResultInfluentialAdvanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
Remón, J., Ahn, M., Girard, N., Johnson, M. L., Kim, D., Lopes, G. D. L., Jr., Pillai, R. N., Solomon, B., Villacampa, G. J., & Zhou, Q. H. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.022 · Cited by 83 · see citing works
Huang, Z., Su, W., Lu, T., Wang, Y., Dong, Y., Qin, Y., Liu, D., Sun, L., & Jiao, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.578091 · Cited by 77 · see citing works
“…trial, IMpower130, which recruited 723 patients with non-squamous NSCLC tumors with EGFR/ALK wild-type status, was set to evaluate the effectiveness and safety of the combinatorial treatment of atezolizumab than treatment with chemotherapy (carboplatin/nab-paclitaxel)-alone (Cappuzzo et al., 2018).”
MethodPacheco, J. M., Camidge, D. R., Doebele, R. C., & Schenk, E. L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00195 · Cited by 60 · see citing works
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
Berghmans, T., Durieux, V., Hendriks, L. E. L., & Dingemans, A. C. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00090 · Cited by 58 · see citing works
Frederickson, A. M., Arndorfer, S., Zhang, I., Lorenzi, M. F., Insinga, R. P., Arunachalam, A., Burke, T. A., & Simon, G. R. (2019) · Immunotherapy · doi:10.2217/imt-2018-0193 · Cited by 58 · see citing works
Grivas, P. D., Monk, B. J., Petrylak, D. P., Reck, M., Foley, G., Guenther, S., Hennessy, D., Makris, C., & Moehler, M. H. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00665-1 · Cited by 55 · see citing works
Wang, M., Liang, H., Wang, W., Zhao, S., Cai, X., Zhao, Y., Li, C., Cheng, B., Xiong, S., Li, J., et al. (2020) · Cancer · doi:10.1002/cncr.33270 · Cited by 52 · see citing works
“We used updated data to analyze the combined rate.(3-8,10,19-28,34) Except for KEYNOTE 021G (a phase 2 trial),(3,4) the studies were phase 3, international, multicenter trials about PD-L1 inhibitors, chemotherapy, or their combination for the first-line treatment of advanced NSCLC.”
MethodCombining Immunotherapy and Chemotherapy for Non–Small Cell Lung Cancer
Judd, J., & Borghaei, H. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.006 · Cited by 46 · see citing works
Califano, R., Gomes, F., Ackermann, C. J., Rafee, S., Tsakonas, G., & Ekman, S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.010 · Cited by 42 · see citing works
Ackermann, C. J., Reck, M., Paz-Ares, L. G., Barlési, F., & Califano, R. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.007 · Cited by 35 · see citing works
Hoffner, B., Leighl, N. B., & Davies, M. J. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101979 · Cited by 30 · see citing works
Shafique, M. R., & Tanvetyanon, T. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1571036 · Cited by 28 · see citing works
Tun, A. M., Thein, K. Z., Thein, W. L., & Guevara, E. (2019) · Future Science OA · doi:10.2144/fsoa-2019-0081 · Cited by 28 · see citing works
“Subgroup analyses HRs for PFS and OS were conducted based on the degree of PD-L1 expressions (PD-L1 negative; low-PD-L1 expression: PD-L1 tumor proportion score of 1–49% for pembrolizumab trials or PD-L1 expression on 1–49% of tumor cells (TCs) or 1–9% of tumor-infiltrating immune cells (ICs) for atezolizumab trials;…”
MethodTagliamento, M., Genova, C., Rossi, G., Coco, S., Rijavec, E., Bello, M. G. D., Boccardo, S., Grossi, F., & Alama, A. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1627326 · Cited by 29 · see citing works
García, J., Bañobre, J. R., Afonso-Afonso, F. J., Amenedo, M., Manrique, M. C. A., Campos, B., Casal‐Rubio, J., Núñez, N. F., Pérez, J. L. F., Lázaro-Quintela, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072093 · Cited by 28 · see citing works
Kuo, C. S., Wang, C., Huang, Y., Pavlidis, S. P., Liu, C., Ko, H., Chung, F., Lin, T., Wang, C., Guo, Y., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13057 · Cited by 21 · see citing works
Ackermann, C. J., Adderley, H., Franco, A. O., Khan, A. M., Reck, M., & Califano, R. (2020) · Drugs · doi:10.1007/s40265-020-01409-6 · Cited by 20 · see citing works
“In total 21% of patients treated in the control arm had switch maintenance pemetrexed therapy after the induction ChT [11].”
BackgroundInfluentialRen, S., Wang, C., Shen, J., & Zhu, C. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.44 · Cited by 17 · see citing works
“J Thorac Dis 2020;12(4):1615-1620 | http://dx.”
BackgroundNoia, V. D., D’Argento, E., Pilotto, S., Vita, E., Ferrara, M. G., Damiano, P., Ribelli, M., Cannella, A., Virtuoso, A., Fattorossi, A., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02788-1 · Cited by 18 · see citing works
Isla, D., de Castro, J., García‐Campelo, R., LIANES, P., Felip, E., Garrido, P., Paz-Ares, L. G., & Trigo, J. M. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02191-y · Cited by 17 · see citing works
Wang, X., & Jing, J. (2025) · MedComm · doi:10.1002/mco2.70346 · Cited by 19 · see citing works
Redefining Treatment Paradigms in First-line Advanced Non–Small-Cell Lung Cancer
Heigener, D. F., Kerr, K. M., Laing, G. M., Mok, T. S. K., Moiseyenko, F. V., & Reck, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1894 · Cited by 15 · see citing works
Facchinetti, F., Pilotto, S., Metro, G., Baldini, E., Bertolaccini, L., Cappuzzo, F., Delmonte, A., Gasparini, S., Inno, A., Marchetti, A., et al. (2019) · Tumori Journal · doi:10.1177/0300891619857418 · Cited by 14 · see citing works
Self-citationLandre, T., Guetz, G. D., Chouahnia, K., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03070-3 · Cited by 14 · see citing works
Shi, Y., Chen, W., Li, C., Zhang, Y., Bo, M., Qi, S., & Li, G. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-1498 · Cited by 15 · see citing works
“Superior overall survival (OS) and progression-free survival (PFS) were demonstrated with the addition use of ICIs in several previous studies (13-17).”
Methodde Marinis, F., Barberis, M. C. P., Barbieri, V., et al. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1569517 · Cited by 12 · see citing works
“The clinical benefit provided by the addition of atezolizumab to a backbone of platinum-based chemotherapy in treatmentnaive patients with nonsquamous NSCLC was confirmed in two more recent large phase III trials: IMPOWER 132 and IMPOWER 130 [40,41].”
BackgroundMethodCao, R., Ma, J., Zhang, S., Sun, L., Liu, Y., Zhang, X., Jing, W., Huang, L., & Han, C. (2019) · Cancer Medicine · doi:10.1002/cam4.2407 · Cited by 11 · see citing works
Ma, T., Wen, T., Xu, C., Wang, Y., Wei, P., Yang, B., Yi, L., Wang, X., Yan, Z., Wang, J., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.08.002 · Cited by 10 · see citing works
Immune Checkpoint Inhibitors and Non-Small-Cell Lung Cancer Management: 2018 Update
Abdel-Rahman, O. M., & Morris, D. G. (2019) · Immunotherapy · doi:10.2217/imt-2018-0167 · Cited by 11 · see citing works
Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
Remón, J., Esteller, L., & Taus, Á. (2019) · Cancer Management and Research · doi:10.2147/cmar.s164935 · Cited by 11 · see citing works
Tsakonas, G., Ekman, S., Koulouris, A., Adderley, H., Ackermann, C. J., & Califano, R. (2023) · International Journal of Cancer · doi:10.1002/ijc.34628 · Cited by 10 · see citing works
Ciccarese, C., Iacovelli, R., Bria, E., Palazzo, A., Maiorano, B. A., Mosillo, C., Carbone, C., Piro, G., & Tortora, G. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000312 · Cited by 10 · see citing works
Cheng, Y., Li, H., Zhang, L., Liu, J., Yang, C., & Zhang, S. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001560 · Cited by 10 · see citing works
“Similarly, the results of the IMpower130 study showed atezolizumab plus carboplatin and nabpaclitaxel significantly improved the OS and PFS compared with chemotherapy treatment alone.([15]) However, in the IMpower132 study, atezolizumab plus pemetrexed and cisplatin or carboplatin only reached the co-primary endpoint…”
ResultThe role of immune checkpoint inhibitors in advanced non-small cell lung cancer
Pistamaltzian, N. F., Georgoulias, V., & Kotsakis, A. P. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1593828 · Cited by 9 · see citing works
Anaplastic Lymphoma Kinase Mutation–Positive Non–Small Cell Lung Cancer
Serritella, A. V., & Bestvina, C. M. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2019.12.001 · Cited by 8 · see citing works
Gao, J., Song, Y., Kou, X., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7203 · Cited by 7 · see citing works
Resistance to chemoimmunotherapy in non-small-cell lung cancer
Hochmair, M. J. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.09 · Cited by 7 · see citing works
“platinum-based chemotherapy as first-line therapy for advanced NSCLC and a PD-L1 ≥ 1%([20]).”
BackgroundAlternative splicing of HER2: a novel mediator of EGFR TKI resistance
Yochum, Z. A., & Villaruz, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-618 · Cited by 4 · see citing works
“The IMpower 130 trial failed to demonstrate a clinical benefit for the addition of immunotherapy to chemotherapy without bevacizumab in EGFR-mutant NSCLCs (14).”
BackgroundAbsenger, G. (2019) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-019-0488-3 · Cited by 1 · see citing works
Franke, A. J., & Schenk, E. L. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-23-28 · Cited by 1 · see citing works
Krishna, A., Saldanha, E., Marakala, V., Simon, P., George, T. J., Anthony, R., Prabhakar, P., Palatty, P. L., & Baliga, M. S. (2024) · Springer eBooks · doi:10.1007/978-981-99-7141-1_14 · Cited by 1 · see citing works
Leonetti, A., & Tiseo, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821774-0.00014-0 · Cited by 1 · see citing works
Heidegger, I. M., Hilbe, W., & Pircher, A. (2019) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-019-0474-9
Brosseau, S., Gounant, V., Swalduz, A., Avrillon, V., Pérol, M., & Zalcman, G. (2019) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(19)30104-1
Next Generation of Advanced Non-Small Cell Lung Cancer Therapy: Targeted and Immuno-Therapies
Chan, S. W. S., & Smith, E. C. (2020) · International Journal of Medical Students · doi:10.5195/ijms.2020.446
Ospina, A. V., Bruges, R. E., Lema, M., Lopes, G. D. L., Jr., Provencio, M., Gómez, R., Lombana, M., Lobatón, J. F., Yepes, A., Abreo, D., et al. (2019) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.11
Ma, T., Wen, T., Cheng, X., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4134030
- Authors
- Cappuzzo, F., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., Zer, A., Reinmuth, N., Sadiq, A., Archer, V., Ochi Lohmann, T., Wang, L., Kowanetz, M., Lin, W., Sandler, A., & West, H.
- Affiliations
- Azienda Unità Sanitaria Locale Della Romagna (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- William Osler Health System (CA)
- Tennessee Oncology (US)
- Florida Hospital Cancer Institute (US)
- Tel Aviv University (IL)
- Asklepios Fachkliniken München-Gauting (DE)
- Fort Wayne Medical Institute (US)
- Roche (United Kingdom) (GB)
- Genentech (US)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 29
- Pages
- viii742-viii743
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2898490299
- Cited by
- 57
- References
- 0
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 5 · 2020: 16 · 2019: 29 · 2018: 1
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Funders
- Pfizer
- AstraZeneca
- Celgene
- Taiho Pharmaceutical
- Clovis Oncology
- KU Leuven
- Astellas Pharma
- Genentech
- Novartis Pharma
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- atezolizumab, carboplatin, nab-paclitaxel, non-squamous non-small cell lung cancer, first-line therapy, progression-free survival, PD-L1 status, immune checkpoint inhibitors, chemotherapy, safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
